[Evaluation of breast HER2+ cancer pathologic response after a taxan plus trastuzumab-based chemotherapy]

Abstract

Objectives: In our study, we aimed to assess the pathologic complete response after neo-additive chemotherapy that contains a taxan associated to trastuzumab for patients treated from breast cancer at the institute Jean-Godinot between 2012 and 2014, and to evaluate factors associated to this pathologic complete response.

Methods: Retrospective study with clinical, anatomopathologic and radiologic parameters analysis before and after new adjuvant chemotherapy. The statistical analysis was done on logiciel XL-STAT, the Mann-Whitney-Wilcoxon for quantitative variables and Fisher exact tests for qualitative variables, the Spearman rang test.

Results: The rate of pathologic complete response is 38.8%. The prognostic factor associated to pathologic complete response is a Ki-67>44%.

Conclusion: The pathologic complete response rate corresponds to international lower rate; because of the lack of several data, we found out only one prognostic factor, Ki-67>44%.

Keywords: Breast cancer; Cancer du sein; Chimiothérapie néoadjuvante; Neoadjuvant chemotherapy; Pathologic complete response; Réponse histologique complète; Trastuzumab.